WUXIF News and Press, Wuxi AppTec Co. Ltd. - Class H From 03/30/24

2024-03-30 00:10:00 ET Summary I wrote recently about the politically fraught state of the relations of biopharma companies with Chinese outsourcing companies, of which WuXi is probably the most prominent. There are bills in the works in both the House (the BIOSECURE Act) and the ...

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

2024-03-17 03:20:00 ET Summary BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Germany’s Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of ...

2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...

2024-02-08 07:41:00 ET Summary WuXi AppTec, which could be banned from doing business with federal agencies under proposed legislation, derived 65% of its revenue from the U.S. in the first half of last year. The provider of outsourced services to drug makers said it has never spo...

2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...

2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...

2023-03-27 23:00:00 ET Summary Wuxi AppTec’s chemical business doubled last year, but only grew around 40% excluding revenue from Covid-related products and services. The drug outsourcing services company’s net profit fell 47.6% sequentially to 1.44 billion yuan in t...

Summary China pharma company Jinxi Jemincare out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. The oral small-molecule candidate, developed in Jemincare’s R&D center, is currently in preclinical testing. Shanghai IASO Bi...